The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
 
Fiona Taylor
Employment - Adelphi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
 
Meredith M. Regan
Consulting or Advisory Role - Ipsen (Inst); Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dendreon (Inst); Ferring (Inst); Ipsen (Inst); Ipsen (Inst); Janssen (Inst); Medivation (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); OncoGenex (Inst); Pfizer (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Sotio (Inst); TerSera (Inst); Veridex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Rachael Lawrance
Employment - Adelphi
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
 
Alejandro Moreno-Koehler
Employment - Adelphi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
 
Andriy Moshyk
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sumati Rao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Corey Ritchings
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
SRIVIDYA KOTAPATI
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jennifer Lord-Bessen
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb
 
Jasmine I. Rizzo
Employment - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; X4 Pharma
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center; Various
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - BiolineRx; Bristol-Myers Squibb; CytomX Therapeutics; Immunocore; Johnson & Johnson; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck